{
  "hypotheses": [
    {
      "id": "H1",
      "prediction": "IF CBD (logP 6.3) is administered to isolated hepatocytes at clinically relevant bulk concentrations (1-10 \u00b5M), THEN mitochondrial membrane CBD concentration will exceed bulk aqueous concentration by \u226550-fold, achieving local concentrations \u2265100 \u00b5M sufficient for VDAC1 occupancy (Kd ~11 \u00b5M), AND this enrichment will be equivalent (\u00b120%) in healthy hepatocytes vs. HCC cells.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "bulk_CBD_concentration",
          "unit": "\u00b5M",
          "low": 1.0,
          "high": 10.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "membrane_enrichment_factor",
          "unit": "fold",
          "low": 10.0,
          "high": 1000.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "VDAC1_Kd",
          "unit": "\u00b5M",
          "low": 5.0,
          "high": 20.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "mitochondrial_membrane_volume_fraction",
          "unit": "(uniform)",
          "low": 0.001,
          "high": 0.01,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 7.0,
      "experimental_protocol": "Treat primary human hepatocytes and HepG2/Huh7 HCC lines with [\u00b3H]-CBD or deuterated CBD (1, 3, 10 \u00b5M, 30 min, 37\u00b0C). Isolate mitochondria by differential centrifugation, separate membrane fractions by alkaline carbonate extraction, quantify CBD by LC-MS/MS. Normalize to lipid mass by phospholipid assay. Timeline: 4-6 weeks.",
      "expected_outcome": "Membrane enrichment \u226550\u00d7; no significant difference between healthy and cancer cells (ratio within 0.8-1.2).",
      "null_outcome": "Enrichment <50\u00d7 (occupancy problem stands) OR >3\u00d7 difference between cell types (selectivity argument partially rescued).",
      "dose_ranges": {
        "CBD": {
          "doses": [
            1.0,
            3.0,
            10.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "LC-MS/MS quantification of CBD in membrane vs. cytosolic fractions (pmol/mg lipid vs. pmol/mL cytosol)"
      ],
      "controls": [
        "Vehicle (DMSO)",
        "heat-killed cells (passive partitioning control)",
        "valinomycin-treated (\u0394\u03a8m-collapsed",
        "tests if accumulation is potential-dependent)",
        "---",
        "###"
      ]
    },
    {
      "id": "H2",
      "prediction": "IF CBD is applied to reconstituted VDAC1 in planar lipid bilayers, THEN it will NOT produce zero-conductance block events but WILL shift gating to intermediate subconductance states (30-70% of full open conductance), alter voltage-dependent gating (V\u2081/\u2082 shift \u226510 mV), and increase dwell time in subconductance states by \u22653-fold.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "VDAC1_full_open_conductance",
          "unit": "nS",
          "low": 3.5,
          "high": 4.5,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CBD_induced_subconductance",
          "unit": "nS",
          "low": 1.0,
          "high": 3.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "V_half_shift",
          "unit": "mV",
          "low": 5.0,
          "high": 30.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "subconductance_dwell_time_ratio",
          "unit": "fold",
          "low": 1.0,
          "high": 20.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CBD_bilayer_concentration",
          "unit": "\u00b5M",
          "low": 1.0,
          "high": 100.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 6.0,
      "experimental_protocol": "Reconstitute purified human VDAC1 (E. coli-expressed, refolded) into DPhPC planar lipid bilayers. Record single-channel currents at \u00b110 to \u00b160 mV in symmetric 1M KCl before and after cis-side addition of CBD (1, 10, 50, 100 \u00b5M in DMSO, \u22640.1% v/v). Analyze conductance histograms, dwell-time distributions, and voltage-gating curves. Repeat with VDAC2. Timeline: 8-12 weeks.",
      "expected_outcome": "Novel subconductance peaks at 40-70% of full open; V\u2081/\u2082 shift \u226510 mV; no complete block events; similar effects on VDAC2.",
      "null_outcome": "Complete block (zero conductance) events dominating\u2014indicating pore occlusion; OR no effect on gating at any concentration tested.",
      "dose_ranges": {
        "CBD": {
          "doses": [
            1.0,
            10.0,
            50.0,
            100.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "Single-channel conductance histograms",
        "open probability (Po)",
        "voltage-gating curves (G-V)",
        "dwell-time distributions",
        "all-points amplitude histograms"
      ],
      "controls": [
        "DMSO vehicle",
        "DIDS (known VDAC blocker",
        "positive control for occlusion)",
        "cholesterol (lipid-partitioning control with no known gating effect)",
        "K\u00f6nig's polyanion (known gating modifier)",
        "---",
        "###"
      ]
    },
    {
      "id": "H3",
      "prediction": "IF CBD binds VDAC1 with Kd ~11 \u00b5M, THEN it will bind VDAC2 with Kd within 5-fold (2-55 \u00b5M), AND CBD treatment (10-50 \u00b5M) will increase BAK oligomerization and cytochrome c release in healthy hepatocytes, an effect that is rescued by VDAC2 overexpression and phenocopied by VDAC2 knockdown.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "Kd_VDAC1",
          "unit": "\u00b5M",
          "low": 5.0,
          "high": 20.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "Kd_VDAC2",
          "unit": "\u00b5M",
          "low": 2.0,
          "high": 60.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "selectivity_ratio",
          "unit": "fold",
          "low": 0.2,
          "high": 10.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "BAK_oligomerization_EC50",
          "unit": "\u00b5M",
          "low": 5.0,
          "high": 100.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "cytochrome_c_release_threshold",
          "unit": "%",
          "low": 10.0,
          "high": 80.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 7.0,
      "experimental_protocol": "(A) Binding: Express/purify human VDAC1 and VDAC2 in lipid nanodiscs; measure CBD binding by microscale thermophoresis (MST) or ITC. (B) Functional: Treat primary human hepatocytes (\u00b1 VDAC2 siRNA or VDAC2-FLAG overexpression lentivirus) with CBD (5, 10, 25, 50 \u00b5M, 6-24h). Measure BAK oligomerization (BMH crosslinking + western), cytochrome c release (mitochondrial vs. cytosolic fractionation + ELISA), and caspase-3/7 activity. Timeline: 10-14 weeks.",
      "expected_outcome": "Kd ratio <5\u00d7; CBD increases BAK oligomerization and cytochrome c release",
      "null_outcome": "Kd ratio >10\u00d7 (selectivity exists); OR CBD has no effect on BAK/cytochrome c in healthy hepatocytes even at 50 \u00b5M; OR VDAC2 manipulation does not modulate CBD's apoptotic effect.",
      "dose_ranges": {
        "CBD": {
          "doses": [
            5.0,
            10.0,
            25.0,
            50.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "MST/ITC binding curves (Kd)",
        "BAK crosslinking (Western blot)",
        "cytochrome c ELISA",
        "caspase-3/7 luminescence (Caspase-Glo)",
        "Annexin V/PI flow cytometry"
      ],
      "controls": [
        "Vehicle",
        "ABT-737 (BH3 mimetic",
        "positive control for BAK activation)",
        "VDAC2 siRNA alone (no CBD)",
        "scrambled siRNA + CBD",
        "z-VAD-FMK (pan-caspase inhibitor to confirm apoptotic pathway)",
        "---",
        "###"
      ]
    },
    {
      "id": "H4",
      "prediction": "IF CBD is applied to matched primary human hepatocytes and HCC cell lines, THEN the EC50 for GSH depletion (to <50% baseline) will differ by <3-fold between cell types, GSH depletion will require [CBD] \u226520 \u00b5M (above therapeutic free hepatic levels), AND the ROS scavenging capacity ratio (healthy:HCC) will be <2\u00d7 as measured by DCFDA kinetics.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "baseline_GSH_healthy",
          "unit": "mM",
          "low": 5.0,
          "high": 10.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "baseline_GSH_HCC",
          "unit": "mM",
          "low": 2.0,
          "high": 8.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "GSH_depletion_EC50_healthy",
          "unit": "\u00b5M",
          "low": 15.0,
          "high": 80.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "GSH_depletion_EC50_HCC",
          "unit": "\u00b5M",
          "low": 10.0,
          "high": 60.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "ROS_scavenging_ratio",
          "unit": "(normal,",
          "low": 1.0,
          "high": 3.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "therapeutic_free_hepatic_CBD",
          "unit": "\u00b5M",
          "low": 0.5,
          "high": 10.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 9.0,
      "experimental_protocol": "Treat primary human hepatocytes (\u22653 donors) and HCC lines (HepG2, Huh7, SNU-449) with CBD (1, 5, 10, 25, 50, 100 \u00b5M) for 2, 6, 12, 24h. Measure total GSH/GSSG by enzymatic recycling assay (Tietze), ROS by CM-H2DCFDA kinetics (plate reader, 0-60 min post-CBD), mitochondrial superoxide by MitoSOX, and viability by ATP-based assay (CellTiter-Glo). Pre-treat subset with NAC (5 mM) or BSO (100 \u00b5M, GSH synthesis inhibitor). Timeline: 4-6 weeks.",
      "expected_outcome": "GSH depletion EC50 ratio (healthy:HCC) <3\u00d7; both >20 \u00b5M; ROS scavenging ratio <2\u00d7; NAC rescues viability in both cell types similarly.",
      "null_outcome": "EC50 ratio >5\u00d7 (meaningful selectivity exists); OR ROS scavenging ratio >3\u00d7; OR GSH depletion occurs at <10 \u00b5M in HCC but >50 \u00b5M in healthy cells.",
      "dose_ranges": {
        "CBD": {
          "doses": [
            1.0,
            5.0,
            10.0,
            25.0,
            50.0,
            100.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "GSH/GSSG (enzymatic recycling",
        "\u00b5mol/mg protein)",
        "ROS (DCFDA"
      ],
      "controls": []
    }
  ],
  "n_hypotheses": 4,
  "total_calls": 1,
  "latency_s": 53.76
}